Detalles de la búsqueda
1.
A phase 3 safety study of fosnetupitant as an antiemetic in patients receiving anthracycline and cyclophosphamide: CONSOLE-BC.
Cancer;
128(8): 1692-1698, 2022 04 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35045185
2.
Findings of virtual bronchoscopic navigation can predict the diagnostic rate of primary lung cancer by bronchoscopy in patients with peripheral lung lesions.
BMC Pulm Med;
22(1): 270, 2022 Jul 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-35836220
3.
Five-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: pooled analysis of the ONO-4538-05 and ONO-4538-06 studies.
Jpn J Clin Oncol;
51(1): 106-113, 2021 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33020837
4.
Prognostic impact of geriatric assessment in elderly patients with non-small cell lung cancer: an integrated analysis of two randomized phase III trials (JCOG1115-A).
Jpn J Clin Oncol;
51(5): 685-692, 2021 Apr 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-33479759
5.
Disseminated nocardiosis due to Nocardia terpenica.
J Infect Chemother;
27(9): 1365-1368, 2021 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-33910776
6.
Five-year safety and efficacy data from a phase Ib study of nivolumab and chemotherapy in advanced non-small-cell lung cancer.
Cancer Sci;
111(6): 1933-1942, 2020 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-32277531
7.
Thymic epithelial tumor treatment in Japan: analysis of hospital cancer registry and insurance claims data, 2012-2014.
Jpn J Clin Oncol;
50(3): 310-317, 2020 Mar 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31829410
8.
Multicenter, placebo-controlled, double-blind, randomized study of fosnetupitant in combination with palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
Cancer;
125(22): 4076-4083, 2019 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31381152
9.
Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations.
Invest New Drugs;
37(6): 1207-1217, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30790152
10.
A dose-finding randomized Phase II study of oral netupitant in combination with palonosetron .75 mg intravenous for the prevention of chemotherapy-induced nausea and vomiting in Japanese patients receiving highly emetogenic chemotherapy.
Jpn J Clin Oncol;
49(2): 121-129, 2019 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30576544
11.
Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment: EAST-LC.
Int J Clin Oncol;
24(5): 485-493, 2019 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-30830659
12.
Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
Lancet;
390(10089): 29-39, 2017 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28501140
13.
Safety, tolerability, and pharmacokinetic profile of dabrafenib in Japanese patients with BRAF V600 mutation-positive solid tumors: a phase 1 study.
Invest New Drugs;
36(2): 259-268, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28879519
14.
Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non-small cell lung cancer.
Cancer Sci;
108(5): 1000-1006, 2017 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-28266091
15.
Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors.
Invest New Drugs;
35(2): 207-216, 2017 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-27928714
16.
Phase I/II study of docetaxel combined with resminostat, an oral hydroxamic acid HDAC inhibitor, for advanced non-small cell lung cancer in patients previously treated with platinum-based chemotherapy.
Invest New Drugs;
35(2): 217-226, 2017 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28138828
17.
A phase 1 study of ramucirumab in Japanese patients with advanced solid tumors.
Jpn J Clin Oncol;
47(4): 298-305, 2017 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28158463
18.
Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer.
Int J Clin Oncol;
22(1): 70-78, 2017 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-27659294
19.
Pulmonary Tumor Thrombotic Microangiopathy Appearance on Dual-Energy Computed Tomography.
Am J Respir Crit Care Med;
203(6): 759-760, 2021 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33197218
20.
Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
Lancet Oncol;
17(8): 1147-1157, 2016 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-27312053